
This beautiful 15-kilometre hiking trail has just opened on the NSW South Coast (complete with interactive map)
What is the Munjip Trail?
The Munjip Trail is a 15-kilometre coastal walk in the NSW South Coast region, tracing stunning coastlines and beautiful native bushland. The project was born way back in 2010, and after the devastating bushfires of 2019 ripped through the region, the Eurobodalla Council (with support from the Bushfire Local Economic Recovery Fund and other local community funding bodies) invested $6.5 million in upgrading the walking trails between Batehaven and McKenzies Beach, allowing locals and visitors the chance to explore the region's magical coastline. The name 'Munjip' reportedly translates to 'walking together, let's go' in the local Dhurga language. To honour the heritage of the area, you'll find signage, artwork and audio guides along the trail sharing stories of the traditional custodians of the land and waters. And to make your walk a truly immersive experience, the Eurobodalla Council has launched an i nteractive map that will help you plan your adventure and learn about the area as you go.
Where is the Munjip Trail?
The Munjip Trail is located in the Eurobodalla region of NSW, around a four-hour drive south of Sydney. The trail extends from Batehaven to McKenzies Beach, with the starting point at Batehaven about seven minutes' drive from the centre of the coastal town of Batemans Bay. The trail finishes 15 kilometres down the coast at McKenzies Beach, after tracing the clifftops past several stunning beaches (including the picture book-perfect Malua Bay).
How long is the Munjip Trail?
The trail stretches for 15 kilometres along the beautiful Eurobodalla coastline, taking in dramatic headlands and dreamy hidden coves as well as some more urban stretches. If you venture to every optional lookout along the route, you'll be walking 18 kilometres in total – and we'd say it's worth opting in for those extra three kilometres for the views alone.
Is the Munjip Trail an overnight hike?
Without stops, the hike takes around five hours to complete – but it's not the kind of walk you want to rush. We'd recommend driving down south the day before and spending the night in the area, so you have the whole day to enjoy the hike and splash around in the beaches you pass along the way.
Where to stay near the Munjip Trail
Our top pick for accommodation nearby is Shelter: a beautifully restored 1970s beach shack overlooking the waves at Malua Bay (just a few sandy steps away from the trail). With an outdoor shower, sun-soaked deck and carefully curated record collection, it's the perfect base for your indoor-outdoor South Coast escape.
Do you need to book to hike the Munjip Trail?
There's no need to book to do the hike itself, but it's worth booking accommodation in advance. It's also worth thinking ahead when it comes to transport – either make sure you have a pick-up arranged, leave a car a the end point at McKenzies Beach or double-check the local bus timetable to make sure you can get to where you need to be once you've completed the trail.
You can learn more and plan your adventure over here.
Stay in the loop: sign up for our free Time Out Sydney newsletter
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 minutes ago
- Yahoo
Dollar Tree (DLTR) Rose Following the Divestiture
The London Company, an investment management company, released 'The London Company Mid Cap Strategy' second quarter 2025 investor letter. A copy of the letter can be downloaded here. US equities saw a double-digit surge in the second quarter following a sharp decline in the first quarter. The mid-cap composite rose 5.7% (5.5% net) in the second quarter, falling short of the Russell Midcap Index's 8.5% increase. Please review the fund's top 5 holdings to gain insight into their key selections for 2025. In its second quarter 2025 investor letter, The London Company Mid Cap Strategy highlighted stocks such as Dollar Tree, Inc. (NASDAQ:DLTR). Dollar Tree, Inc. (NASDAQ:DLTR) is a discount retailer. The one-month return of Dollar Tree, Inc. (NASDAQ:DLTR) was 11.63%, and its shares gained 10.21% of their value over the last 52 weeks. On July 29, 2025, Dollar Tree, Inc. (NASDAQ:DLTR) closed at $114.99 per share, with a market capitalization of $23.998 billion. The London Company Mid Cap Strategy stated the following regarding Dollar Tree, Inc. (NASDAQ:DLTR) in its second quarter 2025 investor letter: "Dollar Tree, Inc. (NASDAQ:DLTR) – DLTR was a top performer after it reached an agreement in March to sell its underperforming Family Dollar business, a decade-long drag on growth and margins. This divestiture has driven a stock re-rating, reflecting a higher-quality company focused on value creation at the Dollar Tree banner. The recent elimination of the de minimis exemption has yielded positive sentiment towards retailers like DLTR. We remain attracted to its pricing flexibility and margin enhancement opportunity. A shopper browsing through a discount retailers merchandise aisle filled with a wide variety of items. Dollar Tree, Inc. (NASDAQ:DLTR) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 67 hedge fund portfolios held Dollar Tree, Inc. (NASDAQ:DLTR) at the end of the first quarter, which was 64 in the previous quarter. While we acknowledge the potential of Dollar Tree, Inc. (NASDAQ:DLTR) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered Dollar Tree, Inc. (NASDAQ:DLTR) and shared the list of defensive stocks billionaires are buying amid US trade tariff uncertainty. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 minutes ago
- Yahoo
Ultragenyx to Host Conference Call for Second Quarter 2025 Financial Results and Corporate Update
NOVATO, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Tuesday, August 5, 2025, to discuss its financial results and corporate update for the quarter ending June 30, 2025. The live and replayed webcast of the call will be available through the company's website at The replay of the call will be available for three months. About Ultragenyx Pharmaceutical is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease. The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx's strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency. For more information on Ultragenyx, please visit the company's website at: Contact Ultragenyx InvestorsJoshua Higair@ MediaJess Rowlands media@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Yahoo
2 minutes ago
- Yahoo
Marvell Technology stock soars 10% on Microsoft AI chip prospects
-- Marvell Technology (NASDAQ:MRVL) stock surged 10% Wednesday after Fubon Research analysts highlighted the company's potential significant revenue opportunity from Microsoft's (NASDAQ:MSFT) AI chip initiatives. According to Fubon Research, Microsoft has upgraded specifications for its Maia300 chip, which Marvell is developing, from 3nm with HBM3E to a more advanced 2nm with HBM4. While this has pushed the production timeline from the first quarter of 2026 to the fourth quarter, analysts believe the project represents a substantial opportunity for Marvell. The Maia300 chip is expected to begin production with 300,000-400,000 units in the fourth quarter of 2026, ramping up to 1.2-1.5 million units in 2027. With an estimated average selling price of $8,000 per chip, Fubon projects potential revenue of $2.4 billion in 2026 and $10-12 billion in 2027 from this project alone. Analysts noted that Microsoft appears to be placing "higher expectations on Maia300 by MRVL, rather than Maia200 which is its own solution." This shift comes as Microsoft reportedly faces challenges with its internal chip design capabilities, with Fubon indicating the tech giant is likely to "rely more on MRVL for the current generations." The research also highlighted that Microsoft has increased the planned volume for its Maia200 chip from 40,000-60,000 units to 150,000-200,000 units in 2026, compensating for the delayed Maia300 rollout. Fubon's report suggests Microsoft may be more generous in pricing than Amazon (NASDAQ:AMZN) Web Services, with Maia300's $8,000 ASP substantially higher than AWS Trainium 2's $1,500, despite both projects having similar turnkey margins of 55-60%. Related articles Marvell Technology stock soars 10% on Microsoft AI chip prospects Clients buying into summer rally, bracing for later pullback, says BofA's Hartnett These Under-the-Radar Stocks Offer Better Risk-Reward Ratio Than Nvidia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data